Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

393
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
393
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

299
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
299
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

38
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
38
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

232
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
232
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

53
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
53
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

272
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
272

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypertrophic Versus Atrophic Photoaging in Monozygotic Twins: Insights from a Unique Vitiligo Case Report.

Diagnostics (Basel, Switzerland)·2026
Same author

Sulforaphane as a Photoprotective Agent Against UV-Induced Skin Damage and Carcinogenesis: A Scoping Review.

Journal of personalized medicine·2026
Same author

Diagnostic Challenges and Treatment Strategies in Neutrophilic Cicatricial Alopecias: A Narrative Review from Conventional Therapies to New Therapeutic Targets.

Life (Basel, Switzerland)·2026
Same author

Clinical validation of a patient-friendly saliva microsampling approach to monitor perampanel levels in people with epilepsy.

Epilepsia·2026
Same author

A 52-Week Retrospective Italian Study of Flare Characteristics in Adult Atopic Dermatitis Patients Receiving JAK Inhibitors.

International journal of dermatology·2026
Same author

Patch Test Results With Additions to the European Baseline Series, 2021/22-Joint European Results of the ESSCA<sup>A</sup> and the EBS<sup>B</sup> Working Groups of the ESCD, and the GEIDAC<sup>C</sup>.

Contact dermatitis·2026

Related Experiment Video

Updated: Nov 3, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K

Ixekizumab May Improve Renal Function in Psoriasis.

Giuseppe Fabrizio Amoruso1, Steven Paul Nisticò2, Luigi Iannone2

  • 1Unit of Dermatology, Mariano Santo Hospital, 87100 Cosenza, Italy.

Healthcare (Basel, Switzerland)
|June 2, 2021
PubMed
Summary
This summary is machine-generated.

Ixekizumab, an anti-interleukin-17A (IL-17A) drug, improved chronic renal failure in a patient with psoriasis. This suggests IL-17A blockage may benefit renal conditions associated with autoimmune diseases.

Keywords:
chronic renal failureixekizumabpsoriasis

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

579
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

2.0K

Related Experiment Videos

Last Updated: Nov 3, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

579
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

2.0K

Area of Science:

  • Immunodermatology
  • Nephrology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition.
  • Chronic renal failure is linked to inflammatory diseases like psoriasis.
  • Psoriatic patients are at higher risk for chronic kidney disease.

Observation:

  • A patient with stage-three chronic renal failure and psoriasis was treated with ixekizumab.
  • Ixekizumab is a biologic therapy targeting the interleukin-17A (IL-17A) pathway.
  • The patient experienced improvement in renal function following ixekizumab treatment.

Findings:

  • Treatment with ixekizumab led to enhanced renal function in the observed case.
  • The study highlights a potential benefit of IL-17A inhibition for renal impairment in psoriatic patients.
  • This case suggests a link between IL-17A activity and kidney health.

Implications:

  • Targeting IL-17A may offer a novel therapeutic strategy for renal complications in autoimmune conditions.
  • Further clinical trials are warranted to confirm the efficacy of ixekizumab in managing renal impairment.
  • This research opens new avenues for treating kidney disease in the context of inflammatory disorders.